FY2026 Earnings Estimate for CORT Issued By HC Wainwright

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities researchers at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a research note issued on Thursday, October 31st. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $3.67 for the year, up from their previous forecast of $3.55. HC Wainwright currently has a "Buy" rating and a $80.00 target price on the stock. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Corcept Therapeutics' FY2027 earnings at $4.78 EPS and FY2028 earnings at $5.64 EPS.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 25.53% and a net margin of 22.35%. The company had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. During the same quarter last year, the company earned $0.28 earnings per share. Corcept Therapeutics's quarterly revenue was up 47.7% compared to the same quarter last year.

CORT has been the subject of a number of other reports. Truist Financial lifted their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a "buy" rating in a research report on Monday, September 30th. Sandler O'Neill reaffirmed a "buy" rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Piper Sandler upped their target price on Corcept Therapeutics from $38.00 to $67.00 and gave the company an "overweight" rating in a report on Wednesday, September 18th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $38.00 price target on shares of Corcept Therapeutics in a research note on Tuesday, July 30th. Finally, StockNews.com raised shares of Corcept Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Corcept Therapeutics currently has an average rating of "Buy" and an average target price of $65.25.

Corcept Therapeutics Stock Performance

CORT stock traded down $1.35 during trading on Friday, reaching $47.62. 1,462,070 shares of the company were exchanged, compared to its average volume of 1,189,311. The stock's 50 day moving average price is $42.14 and its 200 day moving average price is $34.40. Corcept Therapeutics has a 52-week low of $20.84 and a 52-week high of $50.07. The company has a market cap of $4.98 billion, a P/E ratio of 37.80 and a beta of 0.46.

Institutional Trading of Corcept Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Capital Performance Advisors LLP purchased a new position in shares of Corcept Therapeutics during the 3rd quarter worth about $25,000. Park Place Capital Corp purchased a new stake in shares of Corcept Therapeutics during the 2nd quarter valued at $32,000. Atwood & Palmer Inc. acquired a new stake in shares of Corcept Therapeutics during the 2nd quarter worth $35,000. Kathleen S. Wright Associates Inc. purchased a new position in shares of Corcept Therapeutics in the 3rd quarter worth $36,000. Finally, FinTrust Capital Advisors LLC raised its position in shares of Corcept Therapeutics by 318.7% in the 1st quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company's stock worth $45,000 after buying an additional 1,348 shares during the period. Hedge funds and other institutional investors own 93.61% of the company's stock.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, insider Gary Charles Robb sold 11,000 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total value of $509,080.00. Following the transaction, the insider now directly owns 22,772 shares in the company, valued at approximately $1,053,888.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider William Guyer sold 10,000 shares of Corcept Therapeutics stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $35.30, for a total value of $353,000.00. Following the completion of the sale, the insider now owns 6,039 shares of the company's stock, valued at $213,176.70. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary Charles Robb sold 11,000 shares of the company's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total value of $509,080.00. Following the completion of the transaction, the insider now owns 22,772 shares of the company's stock, valued at $1,053,888.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,101 shares of company stock valued at $972,817 over the last three months. 20.50% of the stock is currently owned by insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.